dc.contributor.author | Mady, Mohamed Fawzy Hamed Attia | |
dc.contributor.author | El-Naggar, Mohamed | |
dc.contributor.author | Hassan, Ashraf S. | |
dc.contributor.author | Awad, Hanem M. | |
dc.date.accessioned | 2018-09-06T08:50:52Z | |
dc.date.available | 2018-09-06T08:50:52Z | |
dc.date.created | 2018-08-31T12:39:33Z | |
dc.date.issued | 2018-05 | |
dc.identifier.citation | El-Naggar, M. et al. (2018) Design, synthesis and antitumor evaluation of novel pyrazolopyrimidines and pyrazoloquinazolines. Molecules, 23(6) | nb_NO |
dc.identifier.issn | 1420-3049 | |
dc.identifier.uri | http://hdl.handle.net/11250/2561133 | |
dc.description.abstract | A series of N-aryl-7-aryl-pyrazolo[1,5-a]pyrimidines 18a–u and N-aryl-pyrazolo[1,5-a] quinazolines 25a–c were designed and synthesized via the reaction of 5-aminopyrazoles 11a–c with enaminones 12a–g or 19, respectively. The new compounds were screened for their in vitro antitumor activity toward liver (HepG-2) and breast (MCF-7) human cancer cells using 3-[4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide MTT assay. From the results, it was found that all compounds showed dose-dependent cytotoxic activities against both HepG-2 and MCF-7 cells. Two compounds 18o and 18a were selected for further investigations. Cell cycle analysis of liver (HepG-2) cells treated with 18o and breast (MCF-7) cells treated with 18a showed cell cycle arrest at G2/M phase and pro-apoptotic activity as indicated by annexin V-FITC staining. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | MDPI | nb_NO |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.subject | pyrazolopyrimidines | nb_NO |
dc.subject | pyrazoloquinazolines | nb_NO |
dc.subject | synthesis | nb_NO |
dc.subject | antitumor activity | nb_NO |
dc.subject | cell cycle analysis | nb_NO |
dc.subject | medisinsk kjemi | nb_NO |
dc.subject | molekyler | nb_NO |
dc.subject | kreftceller | nb_NO |
dc.title | Design, synthesis and antitumor evaluation of novel pyrazolopyrimidines and pyrazoloquinazolines | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | publishedVersion | nb_NO |
dc.rights.holder | © 2018 by the authors | nb_NO |
dc.subject.nsi | VDP::Mathematics and natural science: 400::Chemistry: 440 | nb_NO |
dc.source.volume | 23 | nb_NO |
dc.source.journal | Molecules | nb_NO |
dc.source.issue | 6 | nb_NO |
dc.identifier.doi | 10.3390/molecules23061249 | |
dc.identifier.cristin | 1605820 | |
cristin.unitcode | 217,8,10,0 | |
cristin.unitname | Institutt for kjemi, biovitenskap og miljøteknologi | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |